
Opinion|Videos|August 15, 2023
CheckMate 9ER Trial Updates
Author(s)Rana R. McKay, MD
Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
First Patients Dosed With TLX597-Tx in Trial for mHSPC
4
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
5































